Natural Killer Cell Biology and Cell Therapy – Kalle Malmberg group

The group studies the molecular and cellular basis for NK cell differentiation and repertoire formation in health and disease.

The group is part of the Center for Infectious Medicine (CIM).

Our research

The Malmberg lab focuses on understanding the cellular and molecular mechanisms underlying the formation and diversification of human NK cell repertories. A central aspect of these studies is to examine the dynamic shaping of NK cell function by killer cell immunoglobulin-like receptors (KIR). We are using a wide range of single cell technologies and imaging tools to study the genetic regulatory circuits involved in shaping the interior of the NK cell with a primary focus on lysosomal signaling. 

In more translational efforts, we seek to develop an off-the-shelf NK cell therapy platform and implement new insights into NK cell biology in clinical trials for patients with advanced cancer. We are also seeking to implement new insights into the adaptive-like behavior of NK cells in the next generation of NK cell-based immunotherapy for patients with refractory or relapsing malignancies.

The research group is based both at the Oslo University Hospital and at Karolinska Institutet and is active within the NextGenNK competence center.

Keywords

NK cells, killer cell immunoglobulin-like receptors, KIR, allogeneic hematopoietic stem cell transplantation, immunotherapy, cell therapy.

Immunotherapy

In a film produced by Cancerfonden, Professor Kalle Malmberg talks about the group's research and explains how it is possible to teach the immune system to take on cancer cells (in Swedish).

Interview with Kalle Malmberg about Immunotherapy

Malmberg group

Open positions

We always want to get in touch with highly motivated students and potential postdocs. If you are interested in doing research within our group, please contact the Group leader

Follow us on Twitter

Publications

Selected publications

Funding

  • ALF
  • Barncancerfonden
  • Cancerfonden
  • EU Horizon 2020
  • Fate Therapeutics
  • KAW
  • Merck
  • SSF
  • Vetenskapsrådet
  • Vinnova

Staff and contact

Group leader

All members of the group

OUS team

Project Manager

  • Lise Kveberg

Lab managers

  • Hanne Julie Hoel
  • Merete Thune Wiiger

Senior engineer

  • Silje Zandstra Krokeide

Postdoctoral fellows

  • Edina Szabo
  • Lamberto Torralba-Raga
  • Karen Martin

Immune informatics and computational biology

  • Herman Netskar

Ph.D. Candidates

  • Marianna Vincenti
  • Thorstein Boxaspen

Master students

  • Alonso Sanchez

Previous lab members

  • Sandra Anderson
  • Bettina Baumann
  • Axel Berg-Larsen
  • Vivien Beziat
  • Mattias Carlsten
  • Kishan Kumar Chudasama
  • Monika Enqvist
  • Cyril Fauriat
  • Jodie Peter Goodridge
  • Benedikt Jakobs
  • Lisa Liu
  • Vincent Oei Yi Sheng
  • Astrid Tschan Plessl
  • Veronika Kremer
  • Aline Pfefferle
  • Shuo-Li
  • Oisin Huhn
  • Petra Balbi
  • Minoru Kanaya
  • Mizuha Kosugi-Kanaya
  • Artur Cieslar-Pobuda
  • Rakesh Kumar
  • Dennis Clement
  • Eivind Heggernes Ask
  • Daniel Alfredo Palacios Orellana
  • Michelle Lu Sætersmoen
  • Camille Philippon
  • Pouria Momayyezi
  • Quirin Hammer